Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
651,165

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Thermo Fisher (TMO) Expands Capabilities in St. Louis Facility

by Zacks Equity Research

Thermo Fisher (TMO) expands manufacturing capacity at the St. Louis site for Biologics treatment.

Here's Why You Should Buy Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.

LabCorp (LH) to Expand Diagnostics Services With New Deal

by Zacks Equity Research

LabCorp's (LH) recent deal will bring together critical expertise, experience and technology from both organizations to improve the delivery of high-quality patient care.

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

by Zacks Equity Research

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG

by Zacks Equity Research

Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

International expansion and the strong prospects of the CSS segment bode well for Integra (IART).

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

by Zacks Equity Research

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG), led by progress in the Food Safety business and recent product launches.

Medtronic (MDT) to Launch Academic R&D Grants With New Pact

by Zacks Equity Research

Medtronic's (MDT) partnership will enable teachers to improve their skill set, boosting student opportunities to pursue STEM careers in corporate America.

Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails

by Zacks Equity Research

Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.

Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter

by Zacks Equity Research

Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.

Cardinal Health (CAH) Launches Next-Gen Enteral Feeding Pump

by Zacks Equity Research

Cardinal Health's (CAH) Kangaroo OMNI enteral feeding pump, with new portable design and effectiveness in terms of personalized care, is likely to improve the quality of life for patients.

Are Medical Stocks Lagging Align Technology (ALGN) This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring

by Zacks Equity Research

DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

The rapid expansion of Align Technology's (ALGN) business in international markets remains a key growth driver.

CNMD vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

CNMD vs. ALGN: Which Stock Is the Better Value Option?

Reasons to Retain Patterson Companies (PDCO) in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024

by Zacks Equity Research

HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.